🚀 VC round data is live in beta, check it out!
Synergy CHC Valuation Multiples
Discover revenue and EBITDA valuation multiples for Synergy CHC and similar public comparables like BioRegenx, Pharmena, Arctic Bioscience, 7FIT and more.
Synergy CHC Overview
About Synergy CHC
Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.
Founded
2010
HQ
Employees
21
Website
Financials (LTM)
EV
$40M
Synergy CHC Financials
Synergy CHC reported last 12-month revenue of $38M and EBITDA of $9M.
In the same LTM period, Synergy CHC generated $28M in gross profit, $9M in EBITDA, and $3M in net income.
Revenue (LTM)
Synergy CHC P&L
In the most recent fiscal year, Synergy CHC reported revenue of $35M and EBITDA of $7M.
Synergy CHC expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $38M | XXX | $35M | XXX | XXX | XXX |
| Gross Profit | $28M | XXX | $24M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $9M | XXX | $7M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $3M | XXX | $2M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | — | — | $27M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Synergy CHC Stock Performance
Synergy CHC has current market cap of $16M, and enterprise value of $40M.
Market Cap Evolution
Synergy CHC's stock price is $1.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $40M | $16M | 0.0% | XXX | XXX | XXX | $0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSynergy CHC Valuation Multiples
Synergy CHC trades at 1.0x EV/Revenue multiple, and 4.2x EV/EBITDA.
EV / Revenue (LTM)
Synergy CHC Financial Valuation Multiples
As of March 21, 2026, Synergy CHC has market cap of $16M and EV of $40M.
Equity research analysts estimate Synergy CHC's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Synergy CHC has a P/E ratio of 5.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16M | XXX | $16M | XXX | XXX | XXX |
| EV (current) | $40M | XXX | $40M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 4.2x | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBIT | 5.6x | XXX | 6.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | 1.7x | XXX | XXX | XXX |
| P/E | 5.5x | XXX | 7.3x | XXX | XXX | XXX |
| EV/FCF | (31.0x) | XXX | (8.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Synergy CHC Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Synergy CHC Margins & Growth Rates
Synergy CHC's revenue in the last 12 month grew by 32%.
Synergy CHC's revenue per employee in the last FY averaged $1.8M.
Synergy CHC's rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Synergy CHC's rule of X is 106% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Synergy CHC Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 26% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 57% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 106% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 35% | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 18% | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Synergy CHC Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioRegenx | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharmena | XXX | XXX | XXX | XXX | XXX | XXX |
| Arctic Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| 7FIT | XXX | XXX | XXX | XXX | XXX | XXX |
| Simris Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Synergy CHC M&A Activity
Synergy CHC acquired XXX companies to date.
Last acquisition by Synergy CHC was on XXXXXXXX, XXXXX. Synergy CHC acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Synergy CHC
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSynergy CHC Investment Activity
Synergy CHC invested in XXX companies to date.
Synergy CHC made its latest investment on XXXXXXXX, XXXXX. Synergy CHC invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Synergy CHC
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Synergy CHC
| When was Synergy CHC founded? | Synergy CHC was founded in 2010. |
| Where is Synergy CHC headquartered? | Synergy CHC is headquartered in United States. |
| How many employees does Synergy CHC have? | As of today, Synergy CHC has over 21 employees. |
| Who is the CEO of Synergy CHC? | Synergy CHC's CEO is Jack Ross. |
| Is Synergy CHC publicly listed? | Yes, Synergy CHC is a public company listed on Nasdaq. |
| What is the stock symbol of Synergy CHC? | Synergy CHC trades under SNYR ticker. |
| When did Synergy CHC go public? | Synergy CHC went public in 2013. |
| Who are competitors of Synergy CHC? | Synergy CHC main competitors are BioRegenx, Pharmena, Arctic Bioscience, 7FIT. |
| What is the current market cap of Synergy CHC? | Synergy CHC's current market cap is $16M. |
| What is the current revenue of Synergy CHC? | Synergy CHC's last 12 months revenue is $38M. |
| What is the current revenue growth of Synergy CHC? | Synergy CHC revenue growth (NTM/LTM) is 32%. |
| What is the current EV/Revenue multiple of Synergy CHC? | Current revenue multiple of Synergy CHC is 1.0x. |
| Is Synergy CHC profitable? | Yes, Synergy CHC is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Synergy CHC? | Synergy CHC's last 12 months EBITDA is $9M. |
| What is Synergy CHC's EBITDA margin? | Synergy CHC's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Synergy CHC? | Current EBITDA multiple of Synergy CHC is 4.2x. |
| What is the current FCF of Synergy CHC? | Synergy CHC's last 12 months FCF is ($1M). |
| What is Synergy CHC's FCF margin? | Synergy CHC's last 12 months FCF margin is (3%). |
| What is the current EV/FCF multiple of Synergy CHC? | Current FCF multiple of Synergy CHC is (31.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.